Clinical Trial Update: A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa [Phase 2]

View source ↗

Summary

Phase 2 trial comparing PK/PD of IPX066 to standard carbidopa-levodopa in Parkinson's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IPX066 (carbidopa-levodopa formulation)
• carbidopa-levodopa (carbidopa-levodopa)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-03-31